Short answer
Rapport Therapeutics, Inc. (RAPP) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results and business highlights announced for quarter ended June 30, 2026.
Rapport Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results and business highlights announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operating details
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 FOS program initiated with FOCUS 1 and FOCUS 2 enrolling, materially advancing RAP-219 toward potential pivotal evidence
- RAP-219 China IND approved, with patient recruitment expected to begin in 4Q 2026
- Bipolar mania Phase 2 topline results expected October 2026, a near-term valuation catalyst
- Cash, cash equivalents and short-term investments of $436.1M expected to fund operations into the second half of 2029
- Net loss widened to $56.6M from $26.7M as R&D expense increased to $51.4M from $22.7M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Rapport Therapeutics, Inc. 8-K filings
Get the next RAPP 8-K as it lands
Follow RAPP for push alerts, or ask the research agent what this filing means.